Clinical Trial Details

Trial ID: L0067
Source ID: NCT03796975
Associated Drug: Pioglitazone
Title: Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease
Acronym: --
Status: Completed
Study Results: No Results Available
Results: --
Conditions: Type 2 Diabetes Mellitus|Non-alcoholic Fatty Liver Disease|Efficacy
Interventions: Drug: Combination of Pioglitazone and Metformin Tablets|Drug: Metformin Hydrochloride Tablets
Outcome Measures: Decreased of liver fat content of fatty liver after 24 weeks treatment as assessed by B-ultrasound|Change of B-cell function after 24 weeks treatment as assessed by homeostasis model assessment of insulin resistance index|Change of liver enzyme after 24 weeks treatment as assessed by blood test|Decreased of HbA1c after 24 weeks treatment as assessed by blood test|Decreased of fasting blood glucose after 24 weeks treatment as assessed by blood test|Change of weight and waistline after 24 weeks treatment as assessed by standard measurement
Sponsor/Collaborators: Xijing Hospital|Second Affiliated Hospital of Xi'an Jiaotong University|Shaanxi Aerospace Hospital|Genertec Universal Xi'an Aero-Engine hospital (Xi' an) Co., Ltd|Xi'an Gaoxin Hospital|Chang'An Hospital|Yan'an people's Hospital|Shangluo Central Hospital
Gender: All
Age: 18 Years to 70 Years ?? (Adult, Older Adult)
Phases: Phase 4
Enrollment: 120
Study Type: Interventional
Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
Start Date: June 28, 2018
Completion Date: November 20, 2019
Results First Posted: --
Last Update Posted: August 7, 2020
Locations: Xijing Hospital, Fourth Military Medical university, Xi'an, Shaanxi, China
URL: https://ClinicalTrials.gov/show/NCT03796975